<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785041</url>
  </required_header>
  <id_info>
    <org_study_id>ASUH7923/16</org_study_id>
    <nct_id>NCT03785041</nct_id>
  </id_info>
  <brief_title>Preemptive and Postoperative Intra-articualr Injection of Levobupivacaine and Tramadol</brief_title>
  <official_title>Comparative Study Between Preemptive and Postoperative Intra-articualr Injection of Levobupivacaine and Tramadol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between preemptive and postoperative intraarticular injection of tramadol on pain
      sensation after arthroscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      220 patients assigned for therapeutic knee arthroscopy were divided into four equal groups in
      this prospective comparative study. All patients received IAI of 20 ml (0.5%) levopubivacaine
      alone in Group C; with 100 mg tramadol as PE (Group PE), at end of surgery (Group PO) or
      divided as 50 mg tramadol + 20 ml 0.25 % levobupivacaine as PE and 50 mg trmadol + 20 ml 0.25
      % levobupivacaine as PO (Group PE/PO). Numeric rating scale (NRS) was used to assess pain
      sensation. Duration till request of rescue analgesia and number of requests were recorded.
      Patients' satisfaction concerning efficacy of PO analgesia was assessed using Iowa
      Satisfaction with Anesthesia Scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain control</measure>
    <time_frame>Pain assessment for 12 hours postoperative</time_frame>
    <description>Pain sensation after arthroscopy assessed by numeric rating scale depending upon patient facial appearance with severe patient expressing high score and no pain with lowest score</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Pain After Knee Arthroscop</condition>
  <arm_group>
    <arm_group_label>Levobupivacaine and tramadol Preemptive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol and levobupivacaine postoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol and levobupivacaine preemptive and postoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine Hydrochloride 2.5 MG/ML</intervention_name>
    <description>Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative</description>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_label>Levobupivacaine and tramadol Preemptive</arm_group_label>
    <arm_group_label>Tramadol and levobupivacaine postoperative</arm_group_label>
    <arm_group_label>Tramadol and levobupivacaine preemptive and postoperative</arm_group_label>
    <other_name>Tramadol 50 MG/ML</other_name>
    <other_name>Tramadol 100 MG/ML</other_name>
    <other_name>Levobupivacaine Hydrochloride 5MG/ML</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient physical status according to American Society of Anesthesiology (ASA) classes
             I-II

          -  Patients free of general diseases prohibiting the use of local anesthesia.

        Exclusion Criteria:

          -  Patients had allergy for local anesthetics or to tramadol

          -  Patients have psychological or neurological disorders inducing difficulty for
             evaluation of pain scoring.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>December 24, 2018</last_update_submitted>
  <last_update_submitted_qc>December 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ayman Anis Metry</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Tramadol</keyword>
  <keyword>Intra-articular injection</keyword>
  <keyword>Preemptive</keyword>
  <keyword>post-arthroscopy pain</keyword>
  <keyword>Levobupivacaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

